文献速递糖尿病肥胖与代谢综合征

有氧训练与司美格鲁肽治疗对2型糖尿病患者胰腺β细胞分泌功能的影响

Effects of Aerobic Training and Semaglutide Treatment on Pancreatic β-Cell Secretory Function in Patients With Type 2 Diabetes.
PubMed 文献 · J Clin Endocrinol Metab · 2023-01-01

31例2型糖尿病患者接受12周有氧训练或同时接受司美格鲁肽治疗,用两步高血糖钳夹评估胰岛素分泌能力。训练和司美格鲁肽均增加胰岛素分泌,两者联合有协同改善β细胞分泌功能的作用。

要点

  • 有氧训练12周增加2型糖尿病患者高血糖钳夹下的胰岛素分泌。
  • 司美格鲁肽治疗增加胰岛素分泌,幅度大于单纯训练。
  • 司美格鲁肽联合有氧训练协同改善β细胞分泌功能。

核心结论

  • 有氧训练与司美格鲁肽治疗联合协同改善β细胞分泌功能。

研究设计与样本

  • 31例2型糖尿病患者随机接受12周单纯有氧训练或同时接受司美格鲁肽治疗。
  • 同时接受司美格鲁肽和训练的患者在训练前接受司美格鲁肽治疗20周,在入组时及训练前后评估。
  • 随机分配至训练的患者在训练前后评估。
  • 主要结局为训练后胰岛素分泌能力的变化,用两步高血糖钳夹(20和30 mM)评估。

主要发现

  • 训练使钳夹第1步胰岛素增量曲线下面积从21增至27 nM×2小时(比值1.28,95%CI 1.02-1.60),第2步从40增至64 nM×2小时(比值1.61,95%CI 1.25-2.07)。
  • 司美格鲁肽治疗使胰岛素分泌相应从16增至111 nM×2小时(比值7.10,95%CI 3.68-13.71),从35增至447 nM×2小时(比值12.74,95%CI 5.65-28.71)。
  • 司美格鲁肽联合训练使胰岛素分泌相应从130增至171 nM×2小时(比值1.31,95%CI 1.06-1.63),从525增至697 nM×2小时(比值1.33,95%CI 1.02-1.72)。
  • 联合治疗总胰岛素分泌增加的中位数比单纯训练多134 nM×2小时(95%CI 108-232)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Prior to this study, it is known that type 2 diabetes is linked to obesity and a sedentary lifestyle, leading to inadequate β-cell function and insulin resistance. Limited research has explored the metabolic effects of combining exercise training with antidiabetic medications, particularly focusing on insulin secretion in patients with type 2 diabetes and moderately preserved β-cell function. OBJECTIVE: The effect of the interaction of semaglutide and physical training on pancreatic β-cell secretory function is unknown in patients with type 2 diabetes. METHODS: Thirty-one patients with type 2 diabetes underwent 12 weeks of aerobic training alone or concurrent to treatment with semaglutide. Patients randomly allocated to concurrent semaglutide and training were treated with semaglutide for 20 weeks before the training and evaluated at inclusion and again before and after the training intervention. Patients randomized to training were evaluated before and after training. The primary outcome was a change in insulin secretory capacity with training, evaluated by a 2-stepped hyperglycemic (20 and 30 mM) clamp. RESULTS: Training increased the incremental area under the curve for insulin from 21 to 27 nM × 2 hours (ratio 1.28, 95% CI 1.02-1.60) during clamp step 1 and from 40 to 64 nM × 2 hours (ratio 1.61, 95% CI 1.25-2.07) during step 2. Semaglutide treatment increased insulin secretion from 16 to 111 nM × 2 hours (ratio 7.10, 95% CI 3.68-13.71), and from 35 to 447 nM × 2 hours (ratio 12.74, 95% CI 5.65-28.71), correspondingly. Semaglutide and training increased insulin secretion from 130 to 171 nM × 2 hours (ratio 1.31, 95% CI 1.06-1.63), and from 525 to 697 nM × 2 hours (ratio 1.33, 95% CI 1.02-1.72), correspondingly. The median increase in total insulin secretion with the combination was 134 nM × 2 hours greater (95% CI 108-232) than with training. CONCLUSION: The combination of aerobic training and semaglutide treatment synergistically improved β-cell secretory function. (ClinicalTrials.gov number, ID NCT04383197).

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Ingersen A, Schmücker M, Alexandersen C, et al. Effects of Aerobic Training and Semaglutide Treatment on Pancreatic β-Cell Secretory Function in Patients With Type 2 Diabetes. J Clin Endocrinol Metab. 2023. PMID: 37265222. doi:10.1210/clinem/dgad326

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。